Quarterly report pursuant to Section 13 or 15(d)

Commitments and contingencies (Details Narrative)

v3.21.2
Commitments and contingencies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Aug. 27, 2021
Sep. 06, 2018
Mar. 17, 2017
Jun. 30, 2021
Sep. 30, 2021
Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Loss Contingency, Lawsuit Filing Date         May 28, 2019  
Description on trial dispute resolution         On November 13, 2019, G Farma filed a Cross-Complaint for declaratory relief and breach of contract relating to the consulting agreement between Mentor and G Farma. The Company filed an answer on December 6, 2019, denying each and every allegation of the Cross-Complaint and intends to vigorously defend itself in this matter.  
G Farma Labs Limited [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Business Acquisition, Equity Interest Issued or Issuable, Description   On March 4, 2019, Addendum VIII increased the G Farma Equity Entities’ equity interest to which Mentor is immediately entitled to 3.843%, and added Goya Ventures, LLC as a G Farma Equity Entity.        
G Farma Labs Limited [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Sale Leaseback Transaction, Net Book Value           $ 622,670
Loss Contingency, Receivable, Proceeds       $ 249,481    
Notes Purchase Agreement [Member] | G Farma Labs Limited [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Purchase of secured promissory notes     $ 500,000      
Increased aggregate principal face amount     1,100,000      
Notes Purchase Agreement [Member] | G Farma Labs Limited [Member] | Secured Promissory Notes [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Monthly payments     10,239      
Ballon payments on notes     $ 894,172      
Equity Purchase and Issuance Agreement [Member] | G Farma Labs Limited [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Business Acquisition, Percentage of Voting Interests Acquired   3.75%        
Settlement Agreement And Mutual Release [Member] | G Farma [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contingent claim description The Settlement Agreement requires the G Farma Entities to pay the Company an aggregate of $500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5 thereafter, until the settlement amount and accrued unpaid interest is paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25%, commencing February 25, 2021, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1%.          
Liability for Unpaid Claims and Claims Adjustment Expense, Net $ 500,000          
Additional outstanding claim $ 2,000,000